.png)
.png)
Dr. Joseph C. McGinley had the honor to be featured as a guest on professional enduro motorcycle racer James Stearns' Inside Enduro podcast. They discussed a common problem motorcycle racers experience: "arm pump".
You can listen to this informational podcast here!
Chronic Exertional Compartment Syndrome (CECS) or “Arm Pump”
​
CECS occurs when increased intramuscular compartment pressure produces severe, sometimes debilitating, pain and neurologic symptoms. Arm Pump in racers is often mis- or un-diagnosed leading to decreased performance, depression, limited engagement in the sport or quitting altogether.
​
The current standard of care is surgery (fasciotomy) which changes the muscle mechanics, creates scar tissue and doesn’t permanently prevent arm pump from returning in a worse way.
​
MVP Treatment™ addresses the underlying cause of CECS — functional venous outflow obstruction—by using image guided botulinum toxin injections to effectively treat CECS.
McGinley Vascular Pressure Treatment™ is a patented, minimally-invasive procedure for CECS.
​
Following a thorough and patented diagnostic evaluation, botulinum toxin is injected using ultrasound guidance into the small segment of muscle that is compressing blood flow. The targeted muscle fibers are locally relaxed allowing blood flow to resume normally.
​
The patient can walk out of the office immediately after the procedure.
​
Dr. McGinley is currently the only provider in the world offering this cutting-edge technique.
30-60
MINUTES
In-office procedure
Local anesthesia
1
OFFICE VISIT
Evaluation and treatment performed on the same day.
Fly in and fly out.
2
DAYS
Limited time away from competitive sports-can be fully unrestricted by 21 days post treatment
87%
SUCCESS RATE
With high-level/elite athletes
Real results
-
87% positive response among patients.
-
First procedure in 2012 with over 1000 patients treated for either leg or arm CECS.
-
Remotely follows each treated patient for up to three years post procedure.
-
Peer-reviewed publication (legs) representing 284 patients. Long-term data have been publicly presented in a poster presentation (see QR code) and are pending publication.
Complications
-
Minor risks, outpatient procedure
-
Main risk is temporarily (4-7 days) diminished grip strength 2-4 weeks after treatment
-
Lower dosing followed by gradual dose-increases helps reduce the rare risk of diminished grip strength
-
Overall risks are lower than surgery (standard of care)
-
Surgery should be the last resort – “do no harm”
Post Procedure Care
Individual care procedures are included in the patient consultation and treatment plan.
48
HOURS
No exercise (upper or lower body)
DAYS
3-14
Unrestricted
DAYS
14-21
Monitor activity for weakness and reduce intensity
DAYS
22+
If asymptomatic without weakness, no restrictions
![MVP Treatment_2021September28[17].jpg](https://static.wixstatic.com/media/7130dc_dc9ee58f28b943cabab9ed92a3d71b9e~mv2.jpg/v1/fill/w_66,h_34,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/MVP%20Treatment_2021September28%5B17%5D.jpg)
Traditional arm pump surgery scars.
![MVP Treatment_2021September28[17] middle.jpg](https://static.wixstatic.com/media/7130dc_2cd48b11262749a5bc1ae0c0d4e8f7dc~mv2.jpg/v1/crop/x_0,y_2,w_332,h_247/fill/w_51,h_38,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/MVP%20Treatment_2021September28%5B17%5D%20middle.jpg)
MRI shows swelling in the forearm muscles (bright areas).
![MVP Treatment_2021September28[17] right.jpg](https://static.wixstatic.com/media/7130dc_5302259c7d3b4b08b503ae5abeacf395~mv2.jpg/v1/crop/x_5,y_2,w_460,h_246/fill/w_65,h_35,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/MVP%20Treatment_2021September28%5B17%5D%20right.jpg)
MVP's less invasive targeting using very small needles.
Click below for Dr. McGinley's featured articles and podcasts:
.jpg)
If you suffer from
compartment syndrome
(CECS, PAES, TOS) of the calf,
click here.
Diagnosis of Chronic Exertional Compartment Syndrome, Popliteal Artery Entrapment Syndrome, Thoracic Outlet Syndrome and a
Non-Surgical Treatment
A recent study analyzed 284 of Dr. McGinley’s patients receiving the MVP treatment. The detailed results are below. In summary, approximately 87% of patients were successfully treated with a 76% reduction in pain. For patients that needed two treatments, 43% had reduction in pain after first treatment.
If you are interested in learning more, you will find the full study below.
